Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Discovery of (3-Phenylcarbamoyl-3,4-dihydro-2<i>H</i>-pyrrol-2-yl) phosphonates as Imidazoline <i>I</i><sub>2</sub> receptor ligands with anti-Alzheimer and analgesic properties

  • Bagán, Andrea
  • López Ruiz, Alba
  • Abás Prades, Sònia
  • Ruiz Cantero, M. Carmen
  • Vasilopoulou, Foteini
  • Taboada Jara, Teresa
  • Griñán Ferré, Christian
  • Pallàs, Mercè
  • Muguruza Millán, Carolina
  • Díez Alarcia, Rebeca
  • Callado Hernando, Luis Felipe
  • Entrena Fernández, José Manuel
  • Cobos del Moral, Enrique José
  • Pérez Fernández, Belén
  • Morales García, José A.
  • Molins, Elies
  • Jonghe, Steven De
  • Daelemans, Dirk
  • Brea Floriani, José Manuel
  • Val García, Cristina
  • Loza García, María Isabel
  • Hernández Hernández, Elena
  • García Sevilla, Jesús A.
  • García-Fuster, M. Julia
  • Díaz Navarro, Caridad
  • Fernández Godino, Rosario
  • Genilloud, Olga
  • Beljkaš, Milan
  • Oljačić, Slavica
  • Nikolic, Katarina
  • Escolano Mirón, Carmen
Imidazoline I2 receptors (I2-IRs) are altered in Alzheimer’s disease (AD) patients and are associated with analgesia. I2-IRs are not structurally described, and their pharmacological characterization relies on their modulation by highly affine ligands. Herein, we describe the synthesis of (3-phenylcarbamoyl-3,4-dihydro-2H-pyrrol-2-yl)phosphonates endowed with relevant affinities for I2-IRs in human brain tissues. The optimal ADME and pharmacokinetic profile of a selected compound, 12d, secured its in vivo exploration in a senescence accelerated prone 8 mice revealing improvement in the cognitive impairment and unveiling the mechanism of action by analyzing specific AD biomarkers. The treatment of a capsaicin-induced mechanical hypersensitivity murine model with 12d revealed analgesic properties devoid of motor coordination issues. The target engagement of 12d was demonstrated by suppression of the analgesic effect by pretreatment with idazoxan. Overall, 12d is a putative candidate for advancing preclinical phases and supports the modulation of I2-IRs as an innovative approach for therapeutics
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Novel Soluble Epoxide Hydrolase Inhibitor: Toward Regulatory Preclinical Studies

  • Jarne-Ferrer, Júlia
  • Sánchez, Javier
  • Codony, Sandra
  • Schneider, Marion
  • Müller, Christa E.
  • Sanfeliu, Coral
  • Franco, Rafael
  • Vazquez, Santiago
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
Neuroinflammation is widely recognized as a key pathological hallmark of Alzheimer's disease (AD). Recently, inhibiting soluble epoxide hydrolase (sEH) has emerged as a promising therapeutic strategy for AD. sEH plays a pivotal role in neuroinflammation by hydrolyzing epoxyeicosatrienoic acids (EETs), which have anti-inflammatory and neuroprotective properties, into pro-inflammatory dihydroepoxyeicosatrienoic acids (DHETs). Furthermore, the overexpression of the enzyme in the brains of AD patients and animal models of the disease highlights its relevance as a therapeutic target. Our previous studies, using the inhibitor UB-SCG-51 demonstrated that sEH inhibition regulates neuroinflammation and other mechanisms, such as the unfolded protein response pathway, while reducing autophagy, apoptosis, and neuronal death, thereby promoting neuroprotection. Building on these findings, we evaluated the arginine salt of the compound, designated UB-SCG-74, which offers improved oral absorption compared to that of UB-SCG-51 while retaining high permeability, potency, and selectivity. In experiments using 5XFAD mice, UB-SCG-74 treatment significantly improved cognition and synaptic plasticity, outperforming donepezil, a standard AD drug, and ibuprofen, an anti-inflammatory drug. Remarkably, these benefits persisted for 4 weeks after administration cessation, suggesting lasting therapeutic effects. Safety pharmacology studies showed no toxicity, supporting the advancement of UB-SCG-74 into preclinical regulatory evaluation. Our findings further indicate that sEH inhibition engages multiple neuroprotective pathways, potentially modifying both AD symptoms and disease progression, thus reinforcing its therapeutic potential., This study was supported by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI) and European Union NextGenerationEU/PRTR (PID2020-118127RB-I00/AEI/10.13039/501100011033 to S.V.; PDC2021-121096/AEI/10. 13039/501100011033 to M.P./C.S. PID2021-127693OB-I00 AEI/10.13039/501100011033 to C.G., PID2021-138079OB-I00 AEI/10.13039/501100011033 to M.P.), and Generalitat de Catalunya (2021 SGR 00357). J.S. was supported by the Research Personnel Training Program (FPI grant PRE2021-099446) of the Spanish Ministerio de Ciencia, Innovación y Universidades (MICIU), and Agencia Estatal de Investigación (AEI). C.G.F. and M.P. belong to María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona, CEX2021-001159-M, Ministry of Science and Innovation). C.E.M. is grateful for support by the Deutsche Forschungsgemeinschaft (DFG) within the Major Research Instrumentation scheme for a highly sensitive HPLC-MS instrument (QTRAP). The paid version of Biorender.com was utilized to prepare the illustrations, Peer reviewed